Gerhard Zugmaier MD

Gerhard Zugmaier is a board certified hematologist and oncologist and full member of the faculty of medicine at the University of Marburg, where he teaches internal medicine. There he had been in charge of the Bone Marrow Transplantation Unit and the Outpatient Clinic. He then joined Roche in 2003 as a Clinical Scientist and was mostly responsible for the design of phase 2 trials of Pertuzumab in ovarian cancer, lung cancer and breast cancer there. Starting in March 2006 he has worked at Micromet AG, which was changed to Amgen Research (Munich) GmbH in March 2012. Gerhard Zugmaier is responsible for the development program of blinatumomab in acute lymphocytic leukemia. He is author of publications in high rank Journals including Science, Leukemia, Haematologica, Lancet Oncology, Journal of Clinical Oncology and Blood.